"I am fortunate to posses had a rewarding occupation of 30 caducity influence the pharmaceutical industry," oral Adulation. "I am further relieved for the big break afforded me by Alfacell, and enjoyed my chronology here. That uttered, I posses decided that any more is the conscientious age to allowance and pursue my interests frontage of industry."
Adulation aggrandized, "I aspiration the control group at Alfacell every accomplishment ascendancy its approaching endeavors. I carry forward steadfast character my acceptance that Alfacell's technology platform is optimistic, and that ONCONASE has great potential as a novel, first - in - class anti - cancer agent. I also feel that the company is well - positioned to achieve the key milestones we have communicated for the coming year."
Kuslima Shogen, Chairman and Chief Executive Officer at Alfacell, stated, "We are indebted to Bob for his exceptional performance. His skilled management of the company's financial strategy and operations was particularly valuable. Under Bob's stewardship, Alfacell has significantly strengthened its balance sheet, as he spearheaded a successful capital campaign to secure resources to complete the ONCONASE Phase IIIb pivotal trial in malignant mesothelioma and advance other preclinical and clinical programs as well. In addition, Bob's contributions to Alfacell's continued growth stretched well beyond his financial duties, as he was able to draw upon his extensive experience in high - profile leadership positions in the industry and execute our business strategy."
Shogen concluded, "On a personal note, Bob will be greatly missed. He has been a respected leader and trusted advisor to me and the Board. We wish him a long, active and fulfilling retirement."
Mr. Love has served as Alfacell's Chief Financial Officer since May 2005.